IPP Bureau
Merck receives positive EU CHMP opinion for pembrolizumab plus chemotherapy as first-line treatment for unresectable non-epithelioid MPM
By IPP Bureau - November 16, 2024
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
Lubrizol and Polyhose ink MoU to set up medical tube manufacturing facility in Tamil Nadu
By IPP Bureau - November 15, 2024
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
Shilpa Medicare Q2 FY25 consolidated PAT up 1,008% at Rs. 18 Cr
By IPP Bureau - November 15, 2024
NABH integrates FOGSI’S maternal health standards across its certification programs
By IPP Bureau - November 15, 2024
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
AstraZeneca invests US$ 3.5 billion in R&D and manufacturing in US
By IPP Bureau - November 14, 2024
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Bristol Myers Squibb showcases cardiovascular portfolio at AHA Scientific Sessions 2024
By IPP Bureau - November 14, 2024
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
AbbVie provides update on Phase 2 results for Emraclidine in schizophrenia
By IPP Bureau - November 14, 2024
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
AstraZeneca Pharma India posts Q2 PAT at Rs. 38.43 Cr
By IPP Bureau - November 14, 2024
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
Cupid Q2 FY25 income up 29.7%; PAT up 96.2%
By IPP Bureau - November 13, 2024
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2
By IPP Bureau - November 13, 2024
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
EMA grants GMP Certificate of compliance to CuraTeQ biosimilars’ Hyderabad facility
By IPP Bureau - November 13, 2024
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Divyesh Maru appointed CFO of Hester Biosciences
By IPP Bureau - November 13, 2024
He specializes in financial planning, audit, compliance and ERP implementation, with extensive experience in leading automation and risk management projects
Hikal Q2 FY25 revenue stood at Rs. 453 Cr
By IPP Bureau - November 13, 2024
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Tata Chemicals Europe to invest Rs. 655 crore on expansion of pharmaceutical grade sodium bicarbonate capacity
By IPP Bureau - November 13, 2024
Construction of the plant will commence in 2025 with first production expected to be in 2027
